The use of the PleurX catheter in the management of non-malignant pleural effusions

Chronic Respiratory Disease

Volumn 8, Issue 3, 2011, Pages 185-191

  Chalhoub, Michel ^a   Harris, Kassem ^a   Castellano, Michael ^a   Maroun, Rabih ^a   Bourjeily, Ghada ^b  

^a STATEN ISLAND UNIVERSITY HOSPITAL   (United States)

^b WOMEN AND INFANTS HOSPITAL   (United States)

Author keywords

Denver; Non malignant; Pleural; Pleurodesis; Pleurx

Indexed keywords

PARACETAMOL; TRAMADOL;

AGED; ARTICLE; B CELL LYMPHOMA; BLEEDING; BREAST CANCER; CATHETER; CATHETERIZATION; COLON CANCER; CONGESTIVE HEART FAILURE; CONTROLLED STUDY; EXUDATIVE PLEURISY; FEMALE; HEPATIC HYDROTHORAX; HUMAN; HYDROTHORAX; IDIOPATHIC EXUDATIVE; LUNG CANCER; MAJOR CLINICAL STUDY; MALE; MESOTHELIOMA; PAIN; PATIENT SATISFACTION; PLEURA EFFUSION; PLEURODESIS; PRIORITY JOURNAL; PROSTATE CANCER; QUESTIONNAIRE; RECURRENT DISEASE;

AGED; AGED, 80 AND OVER; CATHETERS, INDWELLING; FEMALE; HEART FAILURE; HUMANS; HYDROTHORAX; MALE; MIDDLE AGED; PATIENT SATISFACTION; PLEURAL EFFUSION; PLEURAL EFFUSION, MALIGNANT; PLEURODESIS; RECURRENCE; RETROSPECTIVE STUDIES; TIME FACTORS;

EID: 80054872651     PISSN: 14799723     EISSN: 14799731     Source Type: Journal    
DOI: 10.1177/1479972311407216     Document Type: Article

References (34)

1. Kinasewitz GT. Transudative effusions. Eur Respir J 1997; 10: 714-718. (Pubitemid 27112595)
2. Sudduth CD and Sahn SA. Pleurodesis for nonmalig-nant pleural effusions: recommendations. Chest 1992; 102: 1855-1860. (Pubitemid 23001242)
3. Glazer M and Berkman N. Successful talc slurry pleur-odesis in patients with nonmalignant pleural effusion. Chest2000; 117: 1404-1409.
4. Gingell JC. Treatment of chylothorax by producing pleurodesis using iodized talc. Thorax 1965; 20: 261-269.
5. Putterman C, Kramer M, and Ben-Chetrit E. Pleurod-esis for refractory pleural effusion in systemic lupus erythematosus. J Rheumatol 1993; 20: 11.
6. Mouroux J, Perrin C, Venissac N, et al. Management of pleural effusion of cirrhotic origin. Chest 1996; 109: 1093-1096. (Pubitemid 26113657)
7. Davidoff D, Naparstek Y, and Eliakim M. The use of pleurodesis for intractable pleural effusion due to con-gestiveheartfailure. Postgrad Med J1983; 59:330-331. (Pubitemid 13079865)
8. Daniel TM, Tribble CG, and Rodgers BM. Thoraco-scopy and talc poudrage for pneumothoraces and effu-sions. Ann Thorac Surg 1990; 50: 186-189. (Pubitemid 20255937)
9. Mak S, Nyunt K, Wong P, et al. Long-term follow-up of thoracoscopic pleurodesis for hydrothorax compli-cating peritoneal dialysis. Ann Thorac Surg 2002; 74: 218-221. (Pubitemid 34734674)
10. Boutin C, Astoul P, and Seitz B. The role ofthoraco-scopy in the evaluation and management of pleural effusions. Lung 1990; 168: 1113-1121. (Pubitemid 20217770)
11. Tremblay A and Michaud G. Single-center experience with 250 tunneled pleural catheter insertions for malig-nant pleural effusion. Chest 2006; 129: 362-368. (Pubitemid 43289856)
12. Putnam JB, Walsh GL, Swisher SG, et al. Outpatient management of malignant pleural effusion by a chronic indwelling pleural catheter. Ann Thorac Surg 2000; 69: 369-375. (Pubitemid 30125561)
13. Pien GW, Gant MJ, Waham CL, et al. Use of an implantable pleural catheter for trapped lung syndrome in patients with malignant pleural effusion. Chest 2001; 119: 1641-1646. (Pubitemid 32744916)
14. Warren WH, Kim AW, and Liptay MJ. Identification ofclinical factors predicting Pleur X® catheter removal in patients treated for malignant pleural effusion. Eur J Cardio-Thorac 2008; 33: 89-94. (Pubitemid 350266354)
15. Haas AR, Sterman DH, and Musani AI. Malignant pleural effusions management options with consider-ation ofcoding, billing, and a decision approach. Chest 2007; 132: 1036-1041.
16. Herlihy JP, Loyalka P, Gnananandh J, et al. Pleur X® catheter for the management ofrefractory pleural effu-sions in congestive heart failure. Tex Heart IJ 2009; 36: 38-43.
17. Light RW. Pleural effusion. New Engl J Med 2002; 346: 1971-1977. (Pubitemid 34651358)
18. Light RW, Macgregor MI, Luchsinger PC, et al. Pleural effusions: the diagnostic separation oftransu-dates and exudates. Ann Intern Med 1972; 77: 507-513.
19. Parsaei N, Khodaverdian R, Mckelvey AA, et al. Use of long-term indwelling tunnelled pleural catheter for the management of benign pleural effusion. Chest 2006; 130: 271S.
20. Light RW and Vargas FS. Pleural sclerosis for the treatment of pneumothorax and pleural effusion. Lung 1997; 175: 213-223. (Pubitemid 27260310)
21. Xiol X. Hepatic hydrothorax. In: Light RW, Lee YCG (eds.) Textbook of pleural disease. London: Arnold, 2003, pp.402-409.
22. Spencer EB, Cohen DT, and Darcy MD. Safety and efficacy of transjugular intrahepatic portosystemic shunt creation for the treatment ofhepatic hydrothorax. J Vasc Intervent Radiol 2002; 13: 385-390. (Pubitemid 34298817)
23. Boyer TD, Haskal ZJ. The role oftransjugular intrahe-patic portosystemic shunt in the management ofportal hypertension. Hepatology 2005; 41: 386-400. (Pubitemid 40165385)
24. Little AG, Kadowaki MH, Ferguson MK, et al. Pleuro-peritoneal shunting. Alternative therapy for pleural effusions. Ann Surg 1988; 208: 443-450. (Pubitemid 18266460)
25. Genc O, Petrou M, Ladas G, et al. The long-term mor-bidity of pleuroperitoneal shunts in the management of recurrent malignant effusions. Eur J Cardio-Thorac 2000; 18: 143-146. (Pubitemid 30488809)
26. Artemiou O, Marta GM, Klepetko W, et al. Pleurove-nous shunting in the treatment ofnonmalignant pleural effusion. Ann Thorac Surg 2003; 76: 231-233. (Pubitemid 36819747)
27. Park SZ, Shrager JB, Allen MS, et al. Treatment of refractory, nonmalignant hydrothorax with a pleurove-nous shunt. Ann Thorac Surg 1997; 63: 1777-1779. (Pubitemid 27321553)
28. Read CA, Wohlrab JL, Szwed TW, et al. Thoraco-scopy with talc pleurodesis shortens hospitalization. J Broncho Intervent Pulmonol 2002; 9: 281-285. (Pubitemid 35222334)
29. Borgeson DD, Defranchi SA, Lam CSP, et al. Chronic indwelling pleural catheters reduce hospita-lizations in advanced heart failure with refractory pleural effusions. J Cardiac Failure 2009; 15 (Suppl): 105S.
30. Alberts WM, Salem AJ, Solomon DA, et al. Hepatic hydrothorax cause and management. Arch Intern Med 1991; 151: 2383-2388.
31. Riggio O, Merli M, Pedretti G, et al. Hepatic encepha-lopathy after transjugular intrahepatic portosystemic shunt. Dig Dis Sci 1996; 41: 4578-4584.
32. Zhuang ZW, Teng Gj, Jeffery RF, et al. Long-term results and quality of life in patients treated with trans-jugular intrahepatic portosystemic shunts. AJR 2002; 179: 1597-1603. (Pubitemid 35386666)
33. Neragi-Miandoab S. Malignant pleural effusion, cur-rent and evolving approaches for its diagnosis and management. Lung Cancer 2006; 54: 1-9.
34. Ward C, Tudor-Williams G, Cotzias T, et al. Mechan-isms of endotoxin tolerance in patients with alcoholic liver cirrhosis: role of interleukin 10, interleukin 1 receptor antagonist, and soluble tumour necrosis factor receptors as well as effector cell desensitization. Gut 2000; 47: 281-287.